Evidence map›Paper›PMID 25132971›Full record

ReviewJournal of thoracic disease2014

Immunosuppression in lung transplantation.

Jenna L Scheffert, Kashif Raza

Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of thoracic disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04469842 (A Prospective, Randomized, Controlled Pilot Study of Early-Use Long Acting Tacrolimus), which is not on this map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04469842 early_phase1recruitingnot on this mapstarted 2023, after this paper: background citation

A Prospective, Randomized, Controlled Pilot Study of Early-Use Long Acting Tacrolimus (Envarsus XR) in Lung Transplant Recipients

TypeinterventionalSponsorVanderbilt University Medical CenterRan2023 to 2027Enrolled48ConditionsLung Transplant, ComplicationsArmsTacrolimus Extended Release Oral Tablet [Envarsus], Tacrolimus, Mycophenolate Mofetil Hydrochloride, Prednisone, Azathioprine
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 137 citations in OpenAlex.

  1. Trial
  2. A randomized trial of everolimus-based quadruple therapy vs standard triple therapy early after lung transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2019
    Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. [Immunological Aspects after Lung Transplantation].Zentralblatt fur Chirurgie · 2025
    Review
  8. Article
  9. Article
  10. Review
  11. Beyond the organ: lung microbiome shapes transplant indications and outcomes.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2024
    Review
  12. Article
  13. Donor-Specific Blood Transfusion in Lung Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2024
    Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. A Comprehensive Landscape ofTransplant international : official journal of the European Society for Organ Transplantation · 2023
    Article
  19. Clinical course of SARS-CoV-2 infection and recovery in lung transplant recipients.Transplant infectious disease : an official journal of the Transplantation Society · 2022
    Observational
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Jenna L Scheffert1 NewYork-Presbyterian Hospital/Columbia University Medical Center, Department of Pharmacy, USA ; 2 Lung Transplant Program, Department of Pulmonary, Allergy and Critical Care Medicine, Columbia University Medical Center, USA.
Kashif Raza1 NewYork-Presbyterian Hospital/Columbia University Medical Center, Department of Pharmacy, USA ; 2 Lung Transplant Program, Department of Pulmonary, Allergy and Critical Care Medicine, Columbia University Medical Center, USA.
New York Hospital Queens · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lung transplantation can be a life-saving procedure for those with end-stage lung diseases. Unfortunately, long term graft and patient survival are limited by both acute and chronic allograft rejection, with a median survival of just over 6 years. Immunosuppressive regimens are employed to reduce the rate of rejection, and while protocols vary from center to center, conventional maintenance therapy consists of triple drug therapy with a calcineurin inhibitor (cyclosporine or tacrolimus), antiproliferative agents [azathioprine (AZA), mycophenolate, sirolimus (srl), everolimus (evl)], and corticosteroids (CS). Roughly 50% of lung transplant centers also utilize induction therapy, with polyclonal antibody preparations [equine or rabbit anti-thymocyte globulin (ATG)], interleukin 2 receptor antagonists (IL2RAs) (daclizumab or basiliximab), or alemtuzumab. This review summarizes these agents and the data surrounding their use in lung transplantation, as well as additional common and novel therapies in lung transplantation. Despite the progression of the management of lung transplant recipients, they continue to be at high risk of treatment-related complications, and poor graft and patient survival. Randomized clinical trials are needed to allow for the development of better agents, regimens and techniques to address above mentioned issues and reduce morbidity and mortality among lung transplant recipients.

Indexed as

immunosuppressionLung transplantationreview

Identifiers

PMID25132971
PMCPMC4133546
OpenAlexW1837638008

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.